# **GENETICS**

# **Intrinsic disorder controls two functionally distinct dimers ofthe master transcription factor PU.1**

 $\boldsymbol{\mathsf{S}}$ uela Xhani $^1$ , Sangchoon Lee $^1$ , Hye Mi Kim $^1$ , Siming Wang $^1$ , Shingo Esaki $^1$ , Van L. T. Ha $^1$ , Mahtab Khanezarrin<sup>1</sup>, Giselle L. Fernandez<sup>1</sup>, Amanda V. Albrecht<sup>1</sup>, James M. Aramini<sup>2</sup>, **Markus W. Germann1,3 \*, Gregory M. K. Poon1,4 \***

**Transcription factors comprise a major reservoir of conformational disorder in the eukaryotic proteome. The hematopoietic master regulator PU.1 presents a well-defined model of the most common configuration of intrinsically disordered regions (IDRs) in transcription factors. We report that the structured DNA binding domain (DBD) of PU.1 regulates gene expression via antagonistic dimeric states that are reciprocally controlled by cognate DNA on the one hand and by its proximal anionic IDR on the other. The two conformers are mediated by distinct regions of the DBD without structured contributions from the tethered IDRs. Unlike DNA-bound complexes, the unbound dimer is markedly destabilized. Dimerization without DNA is promoted by progressive phosphomimetic substitutions of IDR residues that are phosphorylated in immune activation and stimulated by anionic crowding agents. These results suggest a previously unidentified, nonstructural role for charged IDRs in conformational control by mitigating electrostatic penalties that would mask the interactions of highly cationic DBDs.**

**INTRODUCTION**

Eukaryotic transcription factors are highly enriched in intrinsically disordered regions (IDR), which are sequences that do not adopt a stably structured conformation but are nevertheless essential for activity. Compared with only ~5% in prokaryotes and archaea, more than 80% of eukaryotic transcription factors have extended IDRs (*1*). In the unicellular baker's yeast (*Saccharomyces*), transcription factors comprise the most prodigious functional category of disorderencoding proteins (*2*). In multicellular organisms, ~50% of all residues in eukaryotic factors from model animals (humans, *Drosophila*) and plants (*Arabidopsis*) map to disordered regions (*3*). Clearly, IDRs constitute a major component in eukaryotic gene regulation, and it is therefore important to define their contributions to the molecular properties of transcriptional factors.

While IDRs are generally diverse in sequence, charge characteristics confer specific properties to transcription factor IDRs. For example, positively charged tails mediate diffusion along DNA (*4*) and ubiquitination by E3 ligases of several transcription factors, notably p53 (*5*). More common, however, are negatively charged ("acidic") IDRs such as transactivation domains, which recruit basal factors such as TFIIB and TATA binding protein to the promoter (*6*, *7*), and signaling moieties such as PEST domains that are rich in Glu and Asp residues (*8*, *9*). While IDRs exhibit sequence-dependent conformational preferences on their own, these preferences are also modified by folded domains to which they are tethered (*10*). In transcription factors, IDRs are highly enriched around DNA binding domains (DBDs) (*11*), which display electrostatically biased surfaces to their surroundings. Their DNA contact surfaces are typically rich in positively charged residues while exposing neutral or even negatively charged residues elsewhere. Because DBDs alone represent an incomplete context in functional regulation, our aim is to elaborate

Copyright © 2020 The Authors, some rights reserved: exclusive licensee American Association for the Advancement of Science. No claim to original U.S.Government Works. Distributed under a Creative Commons Attribution **NonCommercial** License 4.0 (CC BY-NC).

the mechanism by which charged, particularly acidic IDRs regulate the recognition of tethered DBDs with each other as well as with target DNA.

As a model system for understanding the impact of intrinsically disordered tethers in transcription factors, the ETS family protein PU.1 exemplifies the most common (known as type I) configuration (*3*), in which its eponymous DBD of ~90 residues comprises the only well-folded structure. The remaining ~170 and 12 residues that flank N- and C-terminally, respectively, are intrinsically disordered sequences. The extended N-terminal IDR consists of an acidic transactivation domain (human residues 1 to 80), a Q-rich domain (residues 81 to 116), and a highly negatively charged PEST domain (residues 117 to 165), all of which are characteristic disordered regions in eukaryotic factors (*9*). This domain architecture, conserved among PU.1 orthologs, commends PU.1 as an ideal model from which more complex transcription factor architectures may be approached.

In addition to the canonical attributes representative of eukaryotic transcription factors, PU.1 is also specifically required for life. During hematopoiesis, all circulating blood cells are ultimately derived from a small population of self-renewing stem cells. PU.1 is a master regulator that is required for the renewal of the hematopoietic stem cells (*12*) and, in collaboration with other factors, directs their differentiation to every major myeloid and lymphoid lineage. Aberrant PU.1 activity is associated with lymphomas (*13*), myeloma (*14*), leukemias (*15*), and Alzheimer's disease (*16*). Most recently, PU.1 was also identified as the key trigger for tissue fibrosis (*17*). Genetic and pharmacologic interventions targeted at PU.1 have established its therapeutic potential in acute myeloid leukemia (*18*, *19*) and fibrotic diseases (*17*). Mechanisms that govern the molecular interactions of PU.1 are therefore relevant to developmental genetics and multiple therapeutic areas including hematology/oncology, immunology, neurology, and rheumatology.

Despite its biological significance, detailed knowledge of the molecular properties of PU.1 has been limited to its structured ETS domain. PU.1 therefore exemplifies the "incomplete context problem" in structural biology, which we have now tackled by addressing the role of the N- and C-terminal IDRs in the behavior of the ETS

<sup>&</sup>lt;sup>1</sup>Department of Chemistry, Georgia State University, Atlanta, GA 30303, USA. <sup>2</sup> Advanced Science Research Center, City University of New York, New York, NY 10031, USA. <sup>3</sup>Department of Biology, Georgia State University, Atlanta, GA 30303, USA.<br><sup>4</sup>Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA <sup>4</sup> Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303, USA.

<sup>\*</sup>Corresponding author. Email: gpoon@gsu.edu (G.M.K.P.); mwg@gsu.edu (M.W.G.)

domain. The data reveal that these tethered IDRs critically control the propensities of the ETS domain to form discrete dimers with and without cognate DNA. These dimeric states, which are conformationally distinct, establish a novel regulatory mechanism that enables negative feedback in PU.1 transactivation. In addition to implications on PU.1 autoregulation in vivo, these results address a general class of problems in which negatively charged IDRs, which are abundant in transcription factors as transactivation and other functional domains, exert direct functional control at the protein/ DNA level.

#### **RESULTS**

The DNA binding (ETS) domain of PU.1 represents its only structured domain, whose 1:1 complex with cognate DNA (Fig. 1A) is structurally conserved in this family of transcription factors. However, in contrast with other ETS members, the ETS domain of PU.1  $(\Delta N165)$  forms 2:1 complexes at single DNA cognate sites in biophysical assays (*20*, *21*). Measurements of self-diffusion by proteinobserved diffusion ordered spectroscopy (DOSY) nuclear magnetic resonance (NMR) showed that inclusion of the N-terminal PEST

domain  $(\Delta N117)$  maintained the DNA binding modes accessible to the ETS domain (Fig. 1B). Specifically, DOSY titrations of both  $\Delta$ N117 and  $\Delta$ N165 with DNA oligomers harboring a single cognate binding site showed two distinct bound states, with the minima in diffusion coefficient occurring sharply at a DNA:protein ratio of 0.5, corresponding to a 2:1 complex. The single minima at DNA:protein = 0.5 excluded the formal possibility of a 2:2 complex or nonspecific binding. If PU.1 were binding DNA nonspecifically beyond the 1:1 complex at equilibrium (i.e., in an unsaturable manner proportional to the concentration of free protein), then the minima in diffusion coefficient would occur at the lowest DNA:protein ratios where protein would be at greatest excess relative to DNA. Independently, protein-into-DNA titrations showed that  $\Delta N117$ enhanced the affinity of the 1:1 complex  $(K_{D1})$  by more than twofold and reduced the affinity of the 2:1 complex  $(K_{D2})$  relative to  $\Delta N165$  by about fourfold (Fig. 1B). Taking the ratio  $K_{D2}/K_{D1}$  as an index of cooperativity in DNA binding, 2:1 complex formation by  $\Delta$ N117 was therefore more negatively cooperative than  $\Delta$ N165. The PEST domain, therefore, preserved the intrinsic binding modes of the ETS domain of PU.1, namely, a 1:1 and 2:1 complex with cognate DNA, while modulating their affinities in solution.





# **PU.1 is self-regulated by negative feedback**

In tissues that natively express PU.1, such as macrophages, PU.1 activity is highly inducible (*22*). The 1:1 complex formed by ETS domains represents the established trans-regulatory complex for ETS transcription factors. Little is understood about the functional nature of the 2:1 complex, for which no ETS analog is known, although its negative cooperative relationship with the 1:1 complex suggests an inactive species (Fig. 1C). To solve this puzzle, we measured PU.1 transactivation in cells using an enhanced green fluorescent protein (EGFP) reporter gene under the control of various synthetic enhancer elements consisting only of tandem copies of the  $\lambda$ B motif (Fig. 1D), a PU.1-specific ETS binding site (EBS) derived from the lymphoid Igλ2-4 enhancer (GenBank X54550). Each consecutive site was spaced by 20 base pairs (bp), or two helical turns, such that bound proteins were arrayed on the same helical face to facilitate the recruitment of the transcriptional machinery. In addition, as the 2:1 complex was known to require an extended site size relative to the monomer (*20*), presenting the bound protein along one helical face would amplify site-site interactions and DNA perturbations, thus rendering most manifest the functional effects of the 2:1 complex.

When transiently transfected into PU.1-negative human embryonic kidney (HEK) 293 cells, the reporters were negligibly activated by endogenous transcription factors, including other ETS family proteins (Fig. 1E). Cotransfection of an expression plasmid encoding full-length PU.1, which was independently tracked by a cotranslating infrared fluorescent protein (iRFP) marker, yielded EGFP fluorescence in a dose-dependent manner. We established a dosing range for the PU.1 expression plasmid that gave a linear variation in PU.1 abundance in HEK293 cells within the physiologically inducible range found in PU.1-expressing myeloid cells (fig. S1). In this configuration, PU.1-dependent transactivation was quantified as the fraction of iRFP-positive cells that were also EGFP positive (Fig. 1E). The functional outcome of an inactive, negatively cooperative 2:1 complex would be a bell-shaped reporter dose-response as the enhancer, which varied in density and spacing of EBS (i.e., cisregulatory syntax), became saturated with nonproductively (2:1) bound PU.1. In the alternative, the reporter signal would dosedependently settle to a saturable level, depending on the level at which the 2:1 complex retained activity relative to the 1:1 complex. The synthetic  $\lambda$ B reporters were therefore well suited to interrogate cellular PU.1 activity, free from the requirement or interference from other promoter-specific cofactors, at the protein/DNA level.

At equivalent PU.1 doses, all enhancer configurations showed graded reporter expression in step with the density of EBS at each enhancer (Fig. 1F). This was consistent with an expected multivalent effect with respect to PU.1 binding sites. However, EGFP expression increased monotonically only with enhancers harboring tandem 3× and 5× EBS. Upon peaking at intermediate PU.1 doses, the 1× and 2× enhancers were repressed by further increases in PU.1. To determine whether the reversal in transactivation involved PU.1 interactions at the enhancer, we mutated the even-numbered sites in the 5×EBS reporter to generate a 3×EBS variant in which the cognate sites doubled in spacing (Fig. 1D). The resultant 3×-alt-EBS reporter exhibited lower transactivation than the more densely spaced 3×EBS, and its reporter signal also no longer increased monotonically (Fig. 1F). The spacing effect, therefore, demonstrated that the functional reversal could not be due solely to PU.1 interactions away from the DNA, which would be inert to syntax changes

at the DNA. The observation of bell-shaped dose response for the 1× and 2× enhancers, but not the 3× or 5×EBS enhancers, suggested additive perturbations of the local DNA structure, which were amplified by the helical spacing of the sites. This interpretation was supported by previous DNA footprinting of the PU.1 ETS domain, which showed strong differences between the singly and doubly PU.1-bound DNA (*20*). Alternatively, binding at the higher-density sites might exhaust a required co-repressing factor for the 2:1 complex. However, this possibility was discounted by the different dose responses exhibited by the 3×EBS and 3×-alt-EBS, which had the same site density, and the occurrence in a cell line (HEK293) that does not natively use PU.1 in gene regulation. Because net transactivation activity was reduced under conditions corresponding to population of the 2:1 complex, the evidence suggested that the 2:1 complex lost activity relative to the 1:1 complex. Thus, manipulation of enhancer syntax (density and spacing) demonstrated negative feedback in PU.1 transactivation in a manner consistent with selftitration of the transcriptionally active 1:1 complex by an inactive dimer bound to DNA.

To extend our functional results to a more physiologic context, we evaluated the impact of graded PU.1 inhibition on three PU.1 target genes in THP-1 cells, a widely used human monocyte/macrophage model. Cells were treated with a PU.1 inhibitor (fig. S2), as a function of dose or incubation period, before stimulation with phorbol 12-myristate 13-acetate (PMA) to mimic PU.1 induction during myeloid differentiation. As PU.1 targets, we examined the *pu.1* (*Spi-1*) gene itself, which is autoregulated (*23*); *csf1ra*, a PU.1 target that encodes the  $\alpha$  subunit of the colony-stimulating factor receptor; and *e2f1*, which is negatively regulated by PU.1 (*24*). We first tested the effect of dose-dependent inhibition of PU.1 for a fixed period of 2 hours on the transcription of these genes by reverse transcription polymerase chain reaction (RT-PCR) (table S2). Expression of *pu.1* and *csf1ra*, both positively regulated PU.1 targets, was increased by lower doses of inhibitor before marked reduction to ~50% at higher doses, yielding bell-shaped profiles (Fig. 1G). In the case of negatively regulated *e2f1*, expression was further inhibited across the dosage range of inhibitor tested. Trans-regulation of all three genes upon dose-dependent inhibition of PU.1 was consistent with an increase in PU.1 activity associated with the relief of negative feedback.

To assess the impact of PU.1 inhibition temporally, we tested a fixed dose of inhibitor (20  $\mu$ M) over time, up to 16 hours before PMA induction. While PU.1 expression gave a bell-shaped dose response at 2 hours of inhibitor exposure, continued exposure at an intermediate (derepressing) dose became strictly inhibitory (Fig. 1G). In contrast, derepression in *csf1ra* expression continued for 8 hours. Expression of the negative-regulated *e2f1* gene, which was dose-dependently reduced at 2 hours of PU.1 inhibition, began to increase by 8 hours of inhibitor exposure. These results thus demonstrated a dynamic nature to the negative feedback that corresponded to the specific effect of PU.1 on the target gene (peaks in activated genes or troughs in repressed genes). The opposing behavior of *csf1ra* and *e2f1* expression, in accordance to their opposite dependence on PU.1, supported the physiologic relevance of PU.1 negative feedback. Last, the latency exhibited by the two target genes relative to the autoregulated *pu.1* gene suggested a combined effect between changes in PU.1 availability at the expression level and competition for binding at the DNA level.

In summary, the expression profiles of *pu.1*, *csf1ra*, and *e2f1* showed that graded PU.1 inhibition led to nonmonotonic changes in trans-regulatory activity in a manner consistent with derepression of negative feedback. Together with the dependence of the synthetic B reporter on PU.1 dose and enhancer syntax (site density and spacing), the data support the biophysically observed 2:1 complex as a functionally relevant species in the cell and motivate specific interest in how the ETS domain dimerizes in its native structural context.

# **The PU.1 PEST domain is an IDR that modulates the stability ofthe 2:1 DNA complex**

Comparison of DNA binding by  $\Delta N117$  and  $\Delta N165$  shows that the N-terminally tethered PEST domain enhanced the affinity of the 1:1 complex but reduced the affinity of the 2:1 complex (Fig. 1B). To better understand the influence of the PEST domain on DNA recognition by PU.1, we first established whether the PEST domain was disordered in the cognate complex by comparing the  $\mathrm{^{1}H\cdot^{15}N}$ heteronuclear single quantum coherence spectroscopy (HSQC) fingerprint region of DNA-bound  $\Delta N165$  and  $\Delta N117$  (Fig. 2A). As with N165 (*20*), the unbound and 1:1 complex gave well-dispersed spectra, while >80% of the cross peaks for 2:1-bound  $\Delta N117$  were broadened out (fig. S3). The similar behavior by the two constructs indicated that broadening was not due to the larger size of the 2:1 complex, in which case broadening would be exacerbated for  $\Delta N117$ . In 1:1-bound N165, whose resonances were well resolved, 88 of the 95 assigned residues overlapped with  $\Delta N117$ , with all PEST residues clustered around  $8.2 \pm 0.2$  parts per million (ppm) on the <sup>1</sup>H dimension, a chemical shift characteristic of disordered structures. Because this region also represented the residues that were detected in HSQC of the 2:1 complex (fig. S3), the evidence suggested similar changes in the chemical environment for the structured ETS domain (represented by the dispersed resonances in intermediate exchange) between free and DNA-bound states of  $\Delta N117$  and  $\Delta N165$ . Thus, the local structure of the ETS domain was not altered upon DNA

binding by the flanking residues, and the PEST domain behaved as a disordered tether in the ETS/DNA complex.

Ligand binding to DNA is generally sensitive to electrostatic interactions. To better understand the impact of the disordered PEST domain on 2:1 complex formation, we probed the electrostatic contribution to site-specific binding by  $\Delta N165$  and  $\Delta N117$  (Fig. 2B). Reducing Na<sup>+</sup> concentration from 0.15 M (as shown in Fig. 1B) to 0.10 M did not affect 2:1 binding by  $\Delta$ N117. However, the biphasic binding indicative of strongly negatively cooperative formation of the 2:1 complex for  $\Delta$ N165 was abolished as the anisotropy values showed. A further reduction to 0.05 M salt resulted in monophasic transitions to the 2:1 complex by both constructs. Notably, binding weakened with decreasing Na<sup>+</sup> concentration and therefore could not reflect simple electrostatic effects on DNA binding. These observations indicated that additional unbound species must regulate DNA recognition by PU.1 and that these species were salt sensitive and controlled by the disordered PEST domain.

#### **The disordered PEST promotes PU.1 homodimerization**

The isolated ETS domain,  $\Delta N165$ , forms a feeble dimer without DNA, as judged by heteronuclear NMR (*25*) as well as static and dynamic light scattering (*21*). To determine the role of the disordered PEST domain in PU.1 dimerization without DNA, we examined several hydrodynamic parameters, which are highly sensitive to selfassociation, of  $\Delta$ N117 as a function of concentration (Fig. 3A). DOSY NMR spectroscopy revealed a marked concentration dependence for the apparent diffusion coefficient. The profile was described by a two-state monomer-dimer equilibrium (detailed in Materials and Methods) with a dissociation constant below 10  $\mu$ M (table S1). To assess concentrations below 50  $\mu$ M, which was limiting for NMR, we performed intrinsic Trp fluorescence anisotropy measurements, which is sensitive to rotational diffusion. N117 exhibited a substantial



**Fig. 2. The intrinsically disordered PEST domain modifies DNA recognition by PU.1. (A) <sup>1</sup>H-<sup>15</sup>N HSQC of ΔN117 and ΔN165 in the 1:1 complex with cognate DNA.** Assignment of the  $\Delta N165$  spectrum was 90% complete. (B) DNA binding by  $\Delta N165$  and  $\Delta N117$  in 0.1 M and 0.05 M NaCl, showing the impact of the PEST domain on the cooperativity of 2:1 complex formation. Parametric values of the equilibrium dissociation constants are given in table S1.

change in steady-state anisotropy that was also described by a twostate dimer with a dissociation constant at below 10  $\mu$ M. In contrast, N165 showed no change. The localization of the three Trp residues in the structured ETS domain of both constructs represented further evidence that the concentration-dependent changes in  $\Delta N117$ involved the ETS domain. Last, high-precision densimetry showed a concentration-dependent transition by  $\Delta N117$  that was again described by two-state dimerization. (Because density varies directly with concentration, density-detected transitions sit on sloped baselines as opposed to the flat baselines in spectrometric titrations.) Relative to the diffusion probes, the densimetric titration gave a higher dissociation constant,  $35 \pm 15 \,\mu$ M. As a control,  $\Delta N165$  gave a concentration-independent partial specific volume (from the slope, see Materials and Methods) of  $0.77 \pm 0.01$  ml/g, a value characteristic of structured globular proteins. Multiple orthogonal probes therefore described a reversible  $\Delta$ N117 dimer that was considerably more avid than  $\Delta N165$ .

We pause to note that concentration dependence of the equilibrium constant (and melting temperatures) rules out monomolecular interactions, such as conformational changes without association. Local conformational changes can and do produce changes in diffusion and volumetric parameters, but this behavior without an intermolecular component cannot depend on total concentration at thermodynamic equilibrium. Artefacts such as aggregation during the experiments



**Fig. 3. The disordered PEST domain in PU.1 drives dimerization in the absence of DNA.** (**A**) Concentration-dependent changes in hydrodynamic and volumetric properties by DOSY NMR, intrinsic Trp fluorescence anisotropy, and high-precision densimetry of ∆N117 in 0.15 M Na<sup>+</sup> at 25°C. Red curves represent fits of the data to a two-state monomer-dimer transition. (**B**) Representative zero-charge ESI mass spectra of  $\Delta N117$  at 13 and 840 µM total concentration, normalized to the height of the monomer (17 kDa) peak. The ratios of the integrated dimer-to-monomer intensities (molecular weight shown) were French-curved to guide the eye. (**C**) Far-UV CD spectra of  $\Delta$ N117 and  $\Delta$ N165 at 25 µM, plotted on a per-molecule basis to highlight the contribution of the N-terminal residues. (D) Concentration-dependent, per-residue spectra of ∆N117 and ∆N165 (left). Dimerization as revealed by singular value decomposition of the ∆N117 spectra and fitted to a two-state transition. (E) <sup>1</sup>H-<sup>15</sup>N HSQC of 400 µM N117 and N165 at 0.15 NaCl. Under these conditions, N117 was predominantly dimeric and N165 was monomeric. The assignments shown are for N117. Inset:  ${^1}H_3^{15}$ N-NOE for  $\Delta$ N117 and  $\Delta$ N165.

are unlikely based on the linear posttransition baselines for all three probes (DOSY NMR, fluorescence anisotropy, and density). Independent evaluation of purified N117 by SDS–polyacrylamide gel electrophoresis (PAGE) and mass spectrometry (MS) (fig. S4) also confirmed the absence of detectable contamination and aggregation. At a deeper level of analysis, the two-state self-association model, given by Eq. 7 in Materials and Methods that fitted the titration data in Fig. 3A, is an *n*th-order polynomial, where *n* is the stoichiometry of the oligomer. The value of *n* (= 2 for dimer), which is fixed in the fitting, imposes a severe constraint on the shape of the titration to which the model may adequately fit. As detailed elsewhere (*26*), oligomers  $n \geq 3$  invariably show sigmoidal (S-shaped) transitions. Only a two-state dimer exhibits nonsigmoidal profiles on linear concentration scales, precisely as constructed in Fig. 3A and observed in the data. On this basis, the biophysical evidence is unambiguous in showing homodimerization of PU.1 without DNA, and the range of dissociation constants yielded by the different probes reflected the distinct molecular properties they sampled.

To further strengthen this evidence, we resolved  $\Delta$ N117 by electrospray ionization (ESI)–MS up to a concentration of 840 µM. Using an established maximum entropy procedure (*27*), peaks corresponding to both monomeric and dimeric PU.1 were observed in deconvoluted zero-charge mass spectra (Fig. 3B). The integrated intensities of the two species were quantitative, but they did not correspond to solution conditions in the other experiments. This was due to the technique's requirement for a volatile buffer  $(NH_4HCO_3)$ , species-dependent ionization efficiency, and the potential for ionization-induced dissociation of the complex. Notwithstanding, the ratio of dimer-tomonomer intensities varied in favor of the dimeric species with increasing total protein concentration (Fig. 3B, bottom). The concentration dependence excluded the possibility that either species could represent a static contaminant but rather corresponded to a N117 monomer and dimer at dynamic equilibrium.

To gain insight into the conformational structure of the free PU.1 dimer, we interrogated  $\Delta N165$  and  $\Delta N117$  by circular dichroism (CD) and NMR spectroscopy. At an identically low concentration  $(25 \mu M)$ , a net contribution of coil content due to the PEST domain was apparent (Fig. 3C). With increasing concentration,  $\Delta N165$ showed a spectral shift but without an endpoint at  $300 \mu$ M. In contrast, the corresponding spectra for  $\Delta N117$  (weighted by contributions from the disordered PEST domain) underwent a nonsigmoidal transition that, unlike  $\Delta N165$ , was substantially completed at 300 µM (Fig. 3D). Model fitting of the far–ultraviolet (UV) CD spectra, which are sensitive to secondary structure content, to a two-state dimer yielded a dissociation constant of  $K_2 = 46 \pm 19 \,\mu$ M. As an analysis of full CD spectra by singular value decomposition rendered more structural information than the other titration probes in Fig. 3A, we will use the CD-fitted  $K_2$  for comparison with other PU.1 constructs and solution conditions.

To probe the local structure of the PU.1 dimer, we compared the 1 <sup>1</sup>H<sup>-15</sup>N HSQC fingerprint of 400  $\mu$ M  $\Delta$ N117 and  $\Delta$ N165, concentrations at which the preceding experiments showed that  $\Delta N117$  was predominantly dimeric, while  $\Delta N165$  remained monomeric (Fig. 3E; compare to Fig. 3A). Dispersed cross-peaks for the two constructs mostly overlapped within experimental uncertainty (inset). PEST domain residues were clustered at  $8.2 \pm 0.2$  ppm.  ${^{1}H}^{15}N\textrm{-}NOE$ (nuclear Overhauser effect) measurements confirmed that the ETS residues in N117 remained well ordered throughout, similarly as N165, while PEST residues exhibited much lower values as a group

(Fig. 3E, inset). Thus, the  $\Delta N117$  dimer was a fuzzy complex in which the PEST domain did not deviate from a tethered IDR to the structured ETS domain.

# **Dimeric forms of PU.1 with and without DNA are nonequivalent**

The 2:1 complex formed by PU.1 at a single cognate site suggested that the PU.1 dimer was asymmetric, as a symmetric dimer that exposes the DNA contact surfaces would logically yield a 2:2 complex. However, this stoichiometry was excluded by the DOSY titration data, which showed two inflections with the least diffusive species at a DNA:protein ratio of 1:2, corresponding to the 2:1 complex (Fig. 1B). Unbound PU.1 also formed a homodimer, which could logically arise only if the complex was symmetric. Experimentally, a symmetric dimer was strongly inferred by a single set of  $^1\mathrm{H}$ -<sup>15</sup>N signals for unbound  $\Delta N117$  at high concentrations (Fig. 3E). Moreover, the CD-detected structure of PU.1 showed negligible changes upon titration by DNA (Fig. 4A), in contrast with the self-titration in the absence of DNA (Fig. 3D). These clues suggested that DNA-bound and free PU.1 dimerized into distinct conformers.

To test these notions, we constructed a constitutive ETS dimer via insertion of a single Cys residue into  $\Delta N165$ , which did not harbor this amino acid, between residues 194 and 195 (Fig. 4B). We targeted this position given its turn conformation in the known structures of the ETS monomer [Protein Data Bank (PDB): 5W3G] and the 1:1 complex (1PUE), and its reported involvement in 2:1 complex formation by heteronuclear NMR (*20*). Purification of this mutant, termed DKCDK, by ion exchange chromatography under nonreducing conditions eluted monomer and its cystine-linked dimer at >1 M NaCl (Fig. 4C). Fractions containing predominantly monomer or dimer were separately dialyzed into a buffer containing 0.15 M NaCl with or without 5 mM dithiothreitol (DTT), respectively. In the absence of DNA, the far-CD spectrum of the DKCDK monomer (maintained with 5 mM DTT) overlapped closely with the spectrum of  $\Delta N165$  (Fig. 4D) and formed the 1:1 complex with cognate DNA similarly as wild-type  $\Delta N165$ , indicating that the Cys insertion was nonperturbative in the DKCDK monomer (Fig. 4E). In stark contrast, the cystine-linked DKCDK dimer exhibited a CD spectrum that was altogether unlike PU.1 at equivalent molar concentrations (400  $\mu$ M). It bore some similarity to a spectrum for  $\Delta N165$  at the highest concentration available (800  $\mu$ M), which contained a greater fraction of dimeric PU.1 (dashed spectrum in Fig. 4D). However, the dimeric DKCDK spectrum was further redshifted by  $\sim$ 7 nm and ~15% more intense. Moreover, the DKCDK dimer bound cognate DNA >100-fold more poorly than wild-type  $\Delta N165$  (Fig. 4E). Thus, the DKCDK mutant showed that a symmetric configuration was severely perturbed in conformation without DNA and unlike DNAbound wild-type  $\Delta N165$  (compare to Fig. 4A). Together with a deficiency in DNA binding, the DKCDK mutant demonstrated that the wild-type DNA-bound dimer was not a symmetric species in contrast with the unbound PU.1 dimer.

To assess the feasibility of an alternative, asymmetric configuration in forming the 2:1 complex, which would involve the DNA contact surface, we then examined an R230A/R233A mutant in the DNArecognition helix H3 of PU.1 (Fig. 4B). The double R→A mutant retained an indistinguishable CD spectrum as wild-type  $\Delta N165$ (Fig. 4F). At a subsaturating concentration of wild-type  $\Delta N165$ , the addition of the mutant at a concentration that showed no DNA binding on its own nevertheless produced strong DNA loading

# SCIENCE ADVANCES | RESEARCH ARTICLE



**Fig. 4. Mutations demonstrate nonequivalent PU.1 dimers with and without DNA.** (**A**) Far-UV CD spectra of the DNA-bound N165 upon subtracting the spectrum of the cognate DNA acquired under identical conditions (75 µM and 0.15 M Na<sup>+</sup>). (**B**) Residues involved in the DKCDK mutant and in the binding-deficient mutant (R230A/ R233A). The structure is homology-modeled against the cocrystal 1PUE. (**C**) Purification of the DKCDK mutant by ion exchange chromatography under nonreducing conditions. Lysate was loaded at 0.5 M NaCl and extensively washed before elution over a linear gradient to 2 M NaCl. SDS-PAGE of purified fractions is shown. Fractions containing primarily monomer (e.g., 1 and 2) or dimers (e.g., 5 onwards) were concentrated and dialyzed separately into buffer containing 0.15 M NaCl with or without 5 mM DTT, respectively. (D) CD spectra of the DKCDK monomer (top) and dimer (bottom) under various conditions with wild-type  $\Delta N165$  as reference. The spectrum for the DKCDK monomer was less well resolved due to the presence of DTT, which contributed to the total absorption of the sample at 50 µM protein. See text for details. (**E**) Fluorescence anisotropy measurements of cognate DNA binding by monomeric and dimeric DKCDK with wild-type N165 as reference. (**F**) CD spectrum of 25 to 100 μM of the R230A/R233A mutant, with ΔN165 at 25 μM as reference. (G) DNA loading by the R230A/R233A mutant in the presence of wild-type ΔN165 (solid symbols). Concentrations of the mutant and wild-type protein that individually failed to bind DNA collaborated to bind DNA as a heterocomplex. (**H**) Proposed model for the formation of two nonequivalent PU.1 dimers: an asymmetric one in the 2:1 DNA complex and a symmetric one without DNA.

(Fig. 4G). Such a result would most simply arise if the  $R \rightarrow A$  mutant associated with the wild-type 1:1 complex to drive the 2:1 heterocomplex. The data thus pointed to an asymmetric PU.1 dimer in the 2:1 complex, in which the secondary structure content of PU.1 did not change significantly. Both features contrast sharply with the symmetric conformation required by the DNA-free dimer.

A synthesis of the evidence leads us to propose a model for PU.1 dimerization in the presence and absence of DNA (Fig. 4H). In terms of affinity, the 1:1 active complex is strongly favored (>10<sup>2</sup>-fold) over either the 2:1 complex or the unbound dimer. Excess PU.1 drives one or the other dimeric state depending on the presence of DNA. The

key cornerstone of this model is the nonequivalence of the two dimeric states. Specifically, the incompatibility of the free dimer with DNA binding means that a preexisting dimer cannot serve as an intermediate for the 2:1 complex. Thermodynamic insulation of the two dimeric species leads to a mutually antagonistic relationship, in which the formation of one species is favored at the expense of the other.  $\Delta N117$  illustrates this antagonism, as relative to  $\Delta N165$ , the N-terminal PEST domain promotes dimerization without DNA and reduces the affinity of 2:1 complex formation (Fig. 1B). Together with enhancing the apparent affinity for 1:1 binding, the result is a widened concentration window for the 1:1 complex for  $\Delta N117$ .

# **The electrostatic basis of PU.1 dimerization**

The ETS domain as embodied by  $\Delta N165$  is highly enriched in Lys and Arg residues, with an isoelectric point (pI) of 10.5. Dimerization should, therefore, be highly sensitive to salt concentration. Contrary to the expectation that the dimer would be stabilized at high salt, which would screen electrostatic repulsion, the opposite was observed. CDdetected self-titration of  $\Delta N165$  at 50 mM  $\mathrm{Na}^+$  showed a nearly complete two-state transition (Fig. 5A) but not at 150 mM Na<sup>+</sup> (compare to Fig. 3A). The low-salt spectra, extended in wavelength to 190 nm and protein concentration to 800 µM because of the reduced Cl<sup>−</sup> level, showed the same transition characteristics as acquired at 150 mM  $\mathrm{Na}^+$  (fig. S5),

indicating that the same transition was inspected at both salt concentrations. Although the transition at 50 mM  $\mathrm{Na}^+$  corresponded to a dissociation constant of  $\sim$ 200 µM, it was still fivefold higher than that for  $\Delta N$ 117 in 150 mM Na<sup>+</sup> (Fig. 5B). The data, therefore, reaffirmed the stimulatory role of the disordered PEST domain in dimerization of the ETS domain while revealing an electrostatic basis in the unbound PU.1 dimer.

The sensitivity of the ETS dimer to salt allowed us to access the local structural changes in the DNA-free ETS dimer by NMR spectroscopy.  $\mathrm{^{1}H\text{-}^{15}N}$  HSQC spectra of  $\Delta \text{N165}$  with 0.5 to 0.025 M NaCl (Fig. 5C) revealed a panel of residues with significant chemical shift



**Fig. 5. Dimerization of the DBD of PU.1 is electrostatically mediated and conformationally destabilizing.** (**A**) CD-detected titration of N167 at 50 mM NaCl from 25 to 800 µM. (**B**) Analysis of the titration by singular value decomposition yields a two-state transition with a dissociation constant *K*<sub>2</sub> of 202 ± 72 µM. (**C**) <sup>1</sup>H-<sup>15</sup>N HSQC as a function of salt from 25 to 500 mM NaCl. Residues with the strongest <sup>1</sup>H-<sup>15</sup>N CSPs (Y173, M223, G239, V244, and L248) are boxed. Inset: Salt dependence of the CSPs of these residues. (**D**) Summary of the residue CSPs with the average %SASA from the unbound NMR monomer, 5W3G. Residues above a 0.5-ppm cutoff are colored in dark blue, and the subset of internal residues (<35% SASA, based on the termini) is marked with yellow circles. Residues implicated in the DNA-bound dimer are marked with green circles. (**E**) Mapping of the high-CSP residues to 5W3G. Green residues mark known residues involved in the DNA-bound dimer (*20*). (**F**) Chemical shift–derived secondary structure prediction via the CSI using <sup>1</sup>H and <sup>15</sup>N signals. The color scheme follows the HSQC in (C). Regions with significant changes in secondary structure are marked by arrows. (G) Near-UV CD-detected thermal melting of  $\Delta N117$  and  $\Delta N165$ . Two salt concentrations were evaluated for  $\Delta N165$  (blue and gray). Inset: Representative near-UV CD spectra. (**H**) DSC thermograms (solid) for  $\Delta N165$  under conditions (salt and concentrations) in which the protein was primarily monomeric or dimeric. The *C*p values are given in kJ (mol monomer)−1 K−1. Dashed curves represent the two-state transition for a monomer (black) and dimer (blue). (**I**) Trp fluorescence-detected denaturation by urea of  $\Delta N117$  and  $\Delta N165$  at two monomer concentrations. Curves represent fit to the linear extrapolation model for a two-state dimer. The marked concentrations represent urea concentration at 50% unfolding.

perturbations (CSPs). Taking the spectrum acquired in 0.5 M NaCl as the reference for monomeric PU.1, the CSPs exhibited a well-ordered salt dependence (Fig. 5C, inset). The salt-induced CSPs were plotted as a function of residues (Fig. 5D), and a cutoff of 0.05 was applied to identify the residues most affected by electrostatic interactions. These perturbed residues were spatially diffuse, as a formal mapping to the unbound PU.1 structure demonstrated (Fig. 5E) and did not overlap with the known residues involved in 2:1 complex formation (*20*). We also examined the transverse spin relaxation  $(T_2)$  properties of the methyl proton peaks in the <sup>1</sup>H spectra as a global representation of the tumbling of  $\Delta N165$  at different NaCl concentrations (fig. S6). The effective  $T_2^*$  relaxation values for the three characteristic methyl  $^1\mathrm{H}$ peaks at 0.025 M NaCl were up to ~25% lower than at 0.5 M NaCl and well beyond experimental error. This result indicated that the salt-induced CSPs reflected the formation of a slower tumbling dimer.

To correlate the NMR data with the CD-detected changes, we used the heteronuclear chemical shifts to infer secondary structure via the chemical shift index (CSI) (*28*). The CSI results corroborated the CDdetected loss of  $\alpha$ -helical and gain in  $\beta$ /coil content and furthermore localized these changes to helix 1 (H1) and the loop between  $\beta$  sheet 3 (S3) and  $\beta$  sheet 4 (S4) (Fig. 5F). Local H1 unwinding accounted for the CSPs observed near the N terminus of  $\Delta N165$ , including the particularly strong CSP at Y173, while the loop between S3 and S4 gained  $\beta$ -sheet structure.

# **Dimeric PU.1 is conformationally destabilized relative to the constituent monomer**

The N-terminal IDR promotes a structurally perturbative PU.1 dimer in the absence of DNA. To reveal the underlying conformational thermodynamics of the PU.1 dimer, we performed thermal melting experiments over a range of protein concentrations, using the near-UV CD spectrum from 250 to 300 nm as a probe. The thermal transition was analyzed from a singular value decomposition of the full spectra at each concentration and fitted to a two-state model. The apparent melting temperature  $(T_m)$  dropped with increasing concentration in step with the propensity for dimer formation (Fig. 5G).  $\Delta N117$  suffered a larger drop than  $\Delta N165$  over a ~10-fold increase in concentration. A reduction in salt concentration, which drove dimerization, similarly caused a larger drop in  $T_m$  for  $\Delta N165$  (0.15 versus 0.05 M Na<sup>+</sup>; Fig. 5G, dashed line).

The presentation of Fig. 5G as  $T_m^{-1}$  versus the logarithm of concentration implies that steeper slopes correspond to lower enthalpies (heats) of dissociation/unfolding, which relate to the quality of conformational interactions. To rigorously define the conformational thermodynamics of the PU.1 dimer, we performed differential scanning calorimetry (DSC) experiments on  $\Delta N165$  under conditions (salt and protein concentrations) where the quantitatively major population was either monomer or dimer (Fig. 5H, all values on a per-mole monomer basis). The thermograms showed a much greater calorimetric molar enthalpy (area under the curve) for the monomer (300  $\mu$ M at 0.15 M Na<sup>+</sup>) than dimer (500  $\mu$ M at 0.05 M Na<sup>+</sup> ). In addition to enthalpy, DSC yields heat capacity changes ( $\Delta C_p$ , difference in the pre- and posttransition baselines) that inform on changes in water-accessible surface area. The  $\Delta N165$ monomer exhibited a  $\Delta C_{\rm p}$  of 3.1  $\pm$  0.3 kJ/(mol K), in good agreement with the structure-based value of 3.3 kJ/(mol K) from the NMR structure of the PU.1 monomer (29). In contrast, the  $\Delta N165$ dimer exhibited a significantly reduced  $\Delta C_p$  of 0.97  $\pm$  0.27 kJ/

Xhani *et al*., *Sci. Adv.* 2020; **6** : eaay3178 21 February 2020

(mol K). Assuming identical thermally unfolded states, the differences in heat capacity changes indicated that  $\Delta N165$  was less well folded than the monomer.

To probe the effect of the N-terminal IDR on the conformational stability of the PU.1 ETS domain, we performed chemical denaturation experiments with urea, which could be reported by intrinsic tryptophan fluorescence at much lower protein concentrations than DSC. At a strictly monomeric concentration (1  $\mu$ M) at 0.15 M Na<sup>+</sup>, N117 was only slightly more sensitive to urea, as judged by the urea concentration at 50% unfolding, than  $\Delta N165$  (Fig. 5I). At 100  $\mu$ M concentration, at which  $\Delta$ N117 is mostly dimeric but  $\Delta$ N165 remains monomeric,  $\Delta N117$  became significantly more sensitive to urea, suggesting highly perturbative interactions between the PEST and ETS domains. A conformationally perturbed  $\Delta N117$  dimer was also implied by its volumetric properties. The posttransition density slope in Fig. 3A yields a partial specific volume of  $\Delta N117$  of 0.85  $\pm$  0.01 ml/g, which is atypically high for structured globular proteins and suggests altered molecular packing and hydration properties.  $\Delta N165$  was more stable at 1  $\mu$ M at 0.05 M Na<sup>+</sup> than at 0.15 M Na<sup>+</sup>, an observation consistent with the ~2°C higher apparent  $T_m$  for 10  $\mu$ M  $\Delta$ N165 over the same  $\mathrm{Na}^+$  concentrations (Fig. 5G). The  $\Delta \mathrm{N165}$  monomer and dimer were therefore opposite in their conformational stabilities with respect to salt, underlining the structure perturbation by salt or the anionic PEST domain.

In summary, spectroscopic and calorimetric measurements showed that the PU.1 ETS dimer was destabilized with respect to unfolding relative to its monomeric constituents. Structural considerations aside, conformational destabilization contributes to the DNA binding deficiency of the apo ETS dimer. A destabilized dimeric state implied favorable concentration-dependent interactions within the unfolded ensemble over the folded state. The ability of the anionic PEST domain to promote formation of the unbound dimer in  $\Delta N117$  therefore further suggests a basis in mitigating the electrostatic repulsion among the cationic ETS domains.

# **The C-terminal IDR is required for PU.1 dimerization without DNA**

In addition to the N-terminal IDR, the structured ETS domain of PU.1 is also tethered at the C terminus to a shorter, 12-residue disordered segment (residues 259 to 270), as apparent in the unbound PU.1 monomer structure (fig. S7A) (*29*). Far-UV CD spectra at 0.15 M  $\mathrm{Na}^+$  showed that hPU.1(117-258) and hPU.1(165-258), termed s $\Delta$ N117 and s $\Delta$ N165, respectively (fig. S7B), lacked the secondary structure changes characteristic of  $\Delta N117$  and  $\Delta 165$  across comparable concentrations (fig. S7C; compare to Fig. 3D). s $\Delta$ N117 was also much less sensitive to urea over the same protein concentration range as  $\Delta$ N117, and s $\Delta$ N165 showed no change relative to  $\Delta$ N165. In contrast to their dimeric deficiency without DNA,  $s\Delta N117$  and  $s\Delta N165$  were both intact with respect to dimerization with cognate DNA (fig. S7D). While s $\Delta$ N117 formed 1:1 and 2:1 DNA complexes with the same affinities as  $\Delta N117$  in 0.15 M NaCl within experimental error,  $s\Delta N165$  was a significantly poorer DNA binder than N165 (table S1). In particular, 2:1 complex formation was less negatively cooperative for  $s\Delta N165$ , with the concentration window  $(K_{D2}/K_{D1})$  for the 1:1 complex only ~65% that for  $\Delta N165$  (fig. S7D). Last, unlike  $\Delta N165$  at 0.05 M Na<sup>+</sup>, s $\Delta N165$  showed a negligible propensity to dimerize and exhibited biphasic binding with cognate DNA (fig. S7E; compare to Fig. 2B). The divergent impact of removing the C-terminal IDR on dimerization with and without DNA



**Fig. 6. Phosphomimetic substitutions at the PEST domain and charged crowding demonstrate a general electrostatic basis of IDR/ETS interactions.** (**A**) Schematic of the phosphorylated Ser residues in human PU.1, marked by green pins. The Ser→Asp substituted positions in D<sub>2</sub>∆N117 and D<sub>4</sub>∆N117 are shown. (**B**) D<sub>2</sub>∆N117 and D<sub>4</sub> $\Delta$ N117 exhibit enhanced dimeric propensities without DNA relative to  $\Delta N$ 117 (compare to Fig. 3D). (C) D<sub>2</sub> $\Delta N$ 117 and D<sub>4</sub> $\Delta N$ 117 are progressively impaired in 2:1 DNA complex formation. (D) The anionic crowders ovalbumin and BSA modulate DNA binding by  $\Delta N117$  in a similar way as the phosphomimetic substitutions on  $\Delta N117$  to an extent that correlates with their sizes and low pls. Inset: Stoichiometric determination using 1 µM DNA (first binding transition in the case of ovalbumin). The spacing of the ordinates is identical to main plots. The surface potentials of the structures were computed using the Adaptive Poisson-Boltzmann Solver (APBS) at 0.15 NaCl.

stood in clear agreement with our concept of nonequivalent dimeric states for PU.1 and the structural distinctiveness of the two states.

#### **Phosphomimetic substitutions of the N-terminal IDR reinforce the dimeric propensity oftheDNA-free PU.1 dimer**

Characteristic of many IDRs flanking DBDs, the N-terminal PEST domain in PU.1 is highly enriched in Glu and Asp residues (pI 3.5), in sharp contrast with the positively charged DBD (pI 10.5) to which it is tethered. The foregoing structural and thermodynamic evidence strongly suggests that the acidic IDR interacts with the ETS domain and shifts it toward dimer formation. Functional studies have established a panel of Ser residues in the PEST domain, including residues 130, 131, 140, and 146 (human numbering), which are multiply phosphorylated in cells (*30*, *31*). Phosphoserines at these positions would enhance the anionic charge density by a substantial amount from  $-11$  (3 Asp + 8 Glu) to  $-17$  ( $\sim$  -1.5 per phosphoserine). Because these residues are disordered, we made phosphomimetic substitutions of these residues to Asp, generating a di-substituted (140 and 146, termed  $D_2\Delta N117$ ) and tetra-substituted mutant (termed  $D_4N117$ ), to probe their general charge-dependent effects (Fig. 6A). Far-UV

sively drove the affinity of the DNA-free dimer, and the resultant dimers appeared to harbor greater random coil content than their wild-type counterpart (Fig. 6B; compare to Fig. 3D). In DNA binding experiments, the di-substituted mutant  $D_2\Delta N117$  behaved approximately as wild-type  $\Delta$ N117, while the affinity of the 2:1 complex for the tetra-substituted mutant  $D_4\Delta N117$  was ~15-fold lower than that for wild-type  $\Delta$ N117 (table S1). Stimulation of the unbound dimer was therefore associated with a marked reduction in the affinity of the 2:1 complex by  $D_4\Delta N117$  (Fig. 6C). As a result, the selective effect on the 2:1 complex in  $D_4\Delta N117$  resulted in greater negative cooperativity (i.e., increasing  $K_{D2}/K_{D1}$ ) in the dimerization of DNA-bound PU.1. In turn, the concentration window for the 1:1 complex widened more than fourfold for  $D_4\Delta N117$  relative to wild-type  $\Delta N117$ .

CD spectra showed that the phosphomimetic substitutions progres-

The reinforcing effects of multiple phosphomimetic substitutions in the disordered PEST domain strongly suggest that it influences the behavior of the ordered ETS domain via a generally electrostatic, nonstructurally specific mechanism. To further establish this notion, specifically the absence of dependence on structurally specific interactions, we tested the effect of crowding concentrations (in the range

of  $10^2$  g/liter) of ovalbumin or bovine serum albumin (BSA) on DNA binding by  $\Delta N165$  (Fig. 6D). These two anionic proteins share pIs  $(pI = 5.2$  and 4.7 for albumin and BSA, respectively) that are close to the PEST domain ( $pI = 3.5$ ) but present well-formed globular structures. If PEST/ETS interactions involved structurally specific interactions between the two domains, the anionic crowders should differ significantly from the PEST domain in their effects on DNA recognition by the ETS domain. DNA binding in the presence of up to 20% (w/v) ovalbumin showed little effect on the 1:1 complex (Fig. 6D, inset) while progressively decreasing the affinity of 2:1 binding. This behavior mirrored closely the phosphomimetic mutants, and similarly, the more pronounced biphasic appearance in the presence of ovalbumin was a result of the increased negative cooperativity and widening concentration window for the 1:1 complex. With BSA, an even more anionic crowder, the effect was correspondingly more pronounced. A concentration of 5% suppressed 2:1 binding at  $10^{-5}$  M, an almost  $10^{5}$ -fold molar excess of  $\Delta N165$ over DNA. Only the 1:1 complex was formed (inset). In contrast, the neutral crowder PEG 8K preserved biphasic DNA binding (fig. S8A), showing that the effects of BSA and ovalbumin were not due to volume exclusion from crowding alone and highlighting the importance of charge. To test our model's prediction that BSA would, therefore, promote the PU.1 dimer, we evaluated  $\Delta N165$  labeled with 5-fluoroTrp by <sup>19</sup>F NMR in the presence of BSA. The three tryptophan residues in  $\Delta N165$  underwent distinct CSPs with 5% BSA under conditions that gave monomers in dilute solution (fig. S8B). These changes reflected conformational perturbations consistent with unbound dimer formation. Thus, phosphomimetic substitutions and acidic crowding supported nonmicrostructural electrostatic field interactions on the ETS domain as the basis of the PEST-stimulated dimerization in the absence of DNA.

# **DISCUSSION**

PU.1 is a markedly inducible transcription factor during hematopoiesis and immune stimulation (*22*). Open-source repositories such as the Human Protein Atlas show that the expression of PU.1 varies among a panel of resting cell lines by ~25-fold. Independently, single-cell cytometry shows that the abundance of PU.1 transcript in unstimulated murine bone marrow cells ranges from less to 5% to ~50% that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (*32*), a housekeeping glycolytic enzyme that is present at ~70  $\mu$ M in the cell (33). Induction by ligands such as retinoic acid (*34*) or bacterial endotoxins (*35*) increases PU.1 expression another 10-fold or more. Depending on the combination of cell line, physiology, and the presence of stimulatory ligands, cellular PU.1 abundance varies by a multiplier comparable to the ratio of the two dissociation constants  $K_{D2}/K_{D1}$  $(10^2$ - to  $10^3$ -fold) of the 1:1 and 2:1 PU.1/DNA complexes.

In patients and animal models, PU.1 dosage is well established as critical to hematopoietic physiology and dysfunction in vivo (*15*, *36*). Dosage effects have been extensively defined in terms of expression, but relatively little is understood about direct dosage effects on transactivation at the protein/DNA level. In this study, manipulation of enhancer syntax in HEK293 cells, which do not use PU.1, demonstrated negative feedback in ectopic PU.1 trans-regulation, independent of modifying interactions with tissue-specific coactivators. The recapitulation of negative feedback, manifested by dose-dependent derepression of endogenous PU.1 in myeloid THP-1 cells, strongly supports functional relevance in native PU.1-dependent gene regulation. Characterization of the attributable species, a 2:1 DNA complex, revealed two nonequivalent dimeric states that are reciprocally controlled by DNA and the IDRs tethered to the structured DBD. Under physiologic salt conditions, structural alterations that bias unbound PU.1 toward dimerization (e.g., full phosphomimetic substitutions of the N-terminal IDR) oppose dimerization of DNA-bound PU.1. Conversely, alterations that abrogate PU.1 dimerization (e.g., truncation of the C-terminal IDR) promote the formation of the 2:1 DNA complex. Only at low salt conditions (e.g., 50 mM Na<sup>+</sup>) are the DNA-free and DNA-bound dimers both favored, and the 1:1 complex is not populated. The tethered IDRs do not appear to become part of the structured dimer but determine preference between the two dimeric states such that the DNA-free dimer remains essentially cryptic without both terminal IDRs.

If the 2:1 complex represents the structural basis of negative feedback, what functional role does the unbound PU.1 dimer play? The thermodynamic relationships among the various states accessible to PU.1 (Fig. 4H), critically the nonequivalent free and DNA-bound dimer, suggest a novel "push-pull" mechanism of PU.1 autoregulation by distinct pools of dimeric protein. By antagonizing the 2:1 complex, we postulate that the unbound dimer suppresses negative feedback and dynamically increases the circulating dose of transcriptionally active PU.1. This model affords for the first time a unifying basis for the PU.1-activating effects of PEST phosphorylation by casein kinase II and protein kinase C (*31*, *37*, *38*), as well as the PU.1-inactivating effects of phosphorylation inhibition by oncogenic transcription factors (*39*), by biasing PU.1 conformations toward or away from the unbound dimer.

Earlier in vitro studies reporting on dimers of the ETS domain (*20*, *21*, *25*), including our own, did not appreciate their functional significance. The solution NMR structure of the unbound monomer (5W3G) reflects the incomplete context afforded by the ETS domain alone (i.e.,  $\Delta N165$ ) at physiologic ionic strength (0.15 M  $\mathrm{Na^+/K^+}$ ). The dissociation constant for the PU.1 dimer in dilute solution ( $10^{-5}$  M) should not be misinterpreted as denoting a physiologically irrelevant interaction. The complex formed by PU.1 and its partner GATA-1 is functionally critical in cell lineage specification during myeloid differentiation in vivo (*40*), but its equilibrium dissociation constant in dilute solution was  $10^{-4}$  M as determined by NMR spectroscopy (*41*). This and other examples show how volume exclusion and other crowding effects favor interactions in vivo relative to dilute solution. Facilitated diffusion along genomic DNA is also expected to promote cognate occupancy beyond the affinity for oligomeric targets from free solution.

As the tethered IDRs remain disordered in fuzzy PU.1 dimers with and without DNA, their formation is therefore unrelated to paradigms such as induced fit, conformational selection, or fly-casting mechanisms that involve order-disorder transitions by the IDRs (*42*, *43*). Instead, the charged intrinsic disorder in PU.1 is involved in throughspace electrostatic interactions. In the absence of the N-terminal IDR, dimerization of the highly cationic ETS domain ( $\Delta N165$ ) is favored by low salt. Conformational destabilization of the resultant dimer under these conditions suggests an electrostatic penalty arising from charge-charge repulsion of the DBDs. The stimulatory effect of the negatively charged IDR on the DNA-free dimer, therefore, arises from attenuation of this repulsive penalty of association. A nonstructurally specific basis is borne out by the similarly favorable effects of reinforcing negative charges via phosphomimetic substitutions in  $\Delta N117$ as anionic crowders on  $\Delta N165$ . As phosphoserines confer higher charge density (~−1.5) than carboxylates, phosphorylation is expected to exert an even greater effect than the phosphomimetic substitutions. Notably, despite its nominal designation as a proteasome-recruiting signal, the PEST domain does not target PU.1 for metabolic turnover, but it is associated with a local role in dimerization and protein-protein partnerships such as with the lymphoid-specific factor IRF4 (*44*).

The properties of the flanking IDRs on DNA binding as revealed in this study highlight the divergent roles played by intrinsic disorder within the ETS transcription factor family, which is united by eponymous, their structurally homologous DBDs. Many ETS members are controlled by autoinhibition, a mechanism that specifically involves short flanking helices in the unbound state that unfolds and disrupts DNA binding allosterically or at the DNA contact interface (*45*). High-affinity binding to native promoters requires coactivators or homodimerization at tandem sites to displace autoinhibitory helices, forming with positive cooperativity 2:2 complexes (*46*). The regulatory strategy is activation through recruitment by other coactivators. In Ets-1, the paradigm autoinhibited ETS member, disordered elements in the serine-rich region (SRR) domain upstream of the autoinhibitory helices further modulate the regulatory potency of the autoinhibitory helices. Progressive phosphorylation of the SRR domain reinforces autoinhibition (*47*). PU.1, and likely its proximal ETS relatives, upends this paradigm. Lacking autoinhibitory domains, high-affinity DNA binding is the default behavior. The disordered elements flanking its structured ETS domain regulate DNA binding by modifying negative feedback. PU.1 is the recruiter in protein-protein partnerships such as IRF4 (*44*). Phosphorylation of the disordered PEST domain promotes the persistence of the active 1:1 complex and has been established as broadly stimulatory (*30*, *31*, *37*, *39*). These contrasting features help frame in molecular and functional terms the evolutionary divergence in the ETS family, one of the most ancient families of transcription regulators in metazoan evolution.

As a final remark, both dimeric forms of PU.1 represent highly novel structures. Asymmetric DNA-bound dimers are known in the case of the zinc finger protein HAP1 (*48*). Zinc fingers are obligate dimers with a 2:2 subunit-to-DNA subsite configuration. Asymmetry in the HAP1 dimer is directed by the polarity of the DNA subsites bound to the subunits. The asymmetric 2:1 complex with PU.1 involves only a single DNA site without significant change in conformation. Functional deficiency of the 2:1 complex as evidenced by the cellular experiments in Fig. 1, therefore, suggests perturbation of DNA structure relative to the singly bound state or denial of specific surfaces of the 1:1 complex to form the transcriptional machinery. In contrast with the localized surface implicated in the 2:1 complex, NMR evidence shows that the residues involved are diffusely distributed with many buried in the PU.1 monomer, leading to a conformationally destabilized dimer. The CSPs observed in the DNA-free dimer, namely, H1 and the wing (S3/S4), were also recently observed for the interaction of PU.1 with a disordered peptide from the SRR domain of Ets-1 (*29*). These regions may, therefore, represent interaction hotspots for protein/protein partnerships for PU.1 in the absence of DNA. Beyond the minimal ETS domain, the short C-terminal IDR acts in concert with the PEST domain to reinforce the dimerizing properties of the ETS domain. Structurally, this suggests that the two IDRs likely interact physically, either antagonistically in the monomeric state or cooperatively in the dimeric state. In the cytoplasm, the ETS domain mediates nuclear import of PU.1 (*49*), so dimerization may also help regulate

subcellular trafficking. Further studies to solve the structures of dimeric PU.1 and map their distributions in subcellular compartments will define their dynamics in vivo and contributions to target gene expression.

# **MATERIALS AND METHODS**

#### **Molecular cloning**

DNA encoding fragments of human PU.1 encompassing the ETS domain with and without various segments of its N- and C-terminal IDRs were synthesized by Integrated DNA Technologies (IDT) (Midland, IA) and subcloned into the Nco I/Hind III sites of pET28b (Novagen). For truncated constructs harboring the PEST domain (i.e.,  $\Delta N117$ , s $\Delta N117$ ,  $D_2\Delta N117$ , and  $D_4\Delta N117$ ),  $Cys^{118}$  was mutated to Ser to facilitate purification and biophysical experiments. Full-length PU.1 used in cell-based experiments was fully wild type. Various PU.1 sensitive enhancer sequences as described in the text were also purchased from IDT and inserted between the Age I/Bgl II sites of pD2EGFP (Clontech, CA). All constructs were verified by Sanger sequencing.

# **Cell culture**

THP-1 and HEK293 cells were purchased from the American Type Culture Collection and were routinely cultured in RPMI 1640 and Dulbecco's modified Eagle's medium, respectively, supplemented with 10% heat-inactivated fetal bovine serum. Where indicated, cells were induced with a single dose of PMA at 16 nM for 72 hours (final dimethyl sulfoxide concentration: 0.1%, v/v). All cell lines were maintained at 37 $\mathrm{^{\circ}C}$  under 5% CO<sub>2</sub>.

# **Cellular reporter assays**

Cellular PU.1 transactivation was measured using a PU.1-dependent EGFP reporter construct under the control of a minimal enhancer harboring only cognate binding sites for PU.1. In PU.1-negative HEK293 cells, the reporter was transactivated in the presence of an expression plasmid encoding wild-type full-length PU.1 and a cotranslating iRFP marker (18). Cells (7  $\times$  10<sup>4</sup>) were seeded in 24well plates and cotransfected with a cocktail consisting of the EGFP reporter plasmid (250 ng) and up to 25 ng of expression plasmids for full-length PU.1, using jetPRIME reagent (Polyplus, Illkirch, France) according to the manufacturer's instructions. The total amount of plasmid was made up to 500 ng with empty  $pCDNA3.1(+)$ vector. Twenty-four hours after transfection, cells were trypsinized and analyzed by flow cytometry using an FCS Fortessa instrument (BD Biosciences). Live cells were gated for iRFP and EGFP fluorescence using reporter and full-length PU.1 only controls, respectively, in FlowJo (BD Biosciences) before computing the total fluorescence of the dually fluorescent population.

#### **RT-PCR experiments**

Following extraction of total RNA using a spin column kit (Omega) and RT (Thermo Fisher Scientific), RT-PCR reactions were performed on a QuantStudio 3 instrument (Applied Biosystems) with SYBR Green PCR Master Mix (Thermo Fisher Scientific). Expression levels of genes were normalized to *gapdh*. The primer sequences used for *pu.1*, *csf1ra*, *e2f1*, and *gapdh* are given in table S2.

# **Protein expression and purification**

Heterologous overexpression in BL21(DE3)pLysS *Escherichia coli* was performed as previously described (*20*). In brief, expression cultures in LB or M9 media (the latter containing  $^{15}NH_4HCl$  or  $U^{-13}C_6$ -glucose as required) were induced at an optical density (OD<sub>600</sub>) of 0.6 with 0.5 mM isopropyl β-p-1-thiogalactopyranoside for 4 hours at 25°C. Uniformly <sup>15</sup>N- and <sup>15</sup>N/<sup>13</sup>C-labeled constructs were expressed in appropriate M9-based media. Harvested cells were lysed in 10 mM NaH2PO4/Na2HPO4 (pH 7.4) containing 0.5 M NaCl by sonication. After centrifugation, cleared lysate was loaded directly onto a HiTrap Sepharose SP column (GE) in 10 mM NaH<sub>2</sub>PO<sub>4</sub>/ Na2HPO4 (pH 7.4) containing 0.5 M NaCl. After extensive washing in this buffer, the protein was eluted in a gradient at  $\sim$ 1 M NaCl in phosphate buffer. Purified protein was dialyzed extensively into various buffers, as described in the text, and diluted as needed with dialysate. Protein concentrations were determined by UV absorption at 280 nm.

# **DNA binding experiments**

DNA binding by protein was measured by steady-state fluorescence polarization of a Cy3-labeled DNA probe encoding the optimal PU.1 binding sequence 5′-AGCGGAAGTG-3′. In brief, 0.5 nM of DNA probe was titrated with protein in a 10 mM tris-HCl buffer (pH 7.4) containing 0.1% (w/v) BSA and NaCl at concentrations as stated in the text. Steady-state anisotropies 〈*r*〉 were measured at 595 nm in 384-well black plates (Corning) in a Molecular Dynamics Paradigm plate reader with 530-nm excitation. The signal represented the fractional bound DNA probe  $(F_b)$ , scaled by the limiting anisotropies of the *i*th bound  $\langle r_i \rangle$  and unbound states  $\langle r_0 \rangle$ , as follows

$$
\langle r \rangle = F_{\rm b}(\sum_{i=1}^{n} \langle r_i \rangle - \langle r_0 \rangle) + \langle r_0 \rangle = F_{\rm b} \sum_{i=1}^{n} \Delta r_i + \langle r_0 \rangle \tag{1}
$$

where  $F_b$  as a function of total protein concentration was fitted to various models as follows. In all cases, the independent variable was the total titrant concentration as taken.

For DNA binding, the two stepwise dissociation constants de-

scribing the formation of the 1:1 and 2:1 PU.1/DNA complexes are  
\n
$$
K_{\text{D1}} = \frac{[\text{P}][\text{D}]}{[\text{PD}]} \qquad (2)
$$
\n
$$
K_{\text{D2}} = \frac{[\text{PD}][\text{P}]}{[\text{P}_2 \text{D}]} = \omega K_{\text{D1}}
$$

where P and D denote PU.1 and DNA. In this analysis, the binding affinities were not further constrained by interactions of the unbound states. The ratio of  $K_{D2}/K_{D1} = \omega$  defines the nature of the cooperativity of the 2:1 complex in the paradigm of McGhee and von Hippel. Values of  $\omega$  below, equal to, or above unity denote positively cooperative, noncooperative, and negatively cooperative formation of the 2:1 complex with respect to the 1:1 complex, respectively.

In direct titrations of the DNA probe by PU.1, the observed anisotropy change represented the summed contributions of the two complexes as expressed by Eq. 1. The most efficient approach is to determine binding in terms of the unbound protein, P. The solution, which is cubic in  $[P]$ , is

$$
0 = \varphi_0 + \varphi_1 [P] + \varphi_2 [P]^2 + \varphi_3 [P]^3
$$
  
\n
$$
\begin{cases}\n\varphi_0 = K_{D1} K_{D2} [P]_t \\
\varphi_1 = K_{D1} K_{D2} - K_{D2} [P]_t + K_{D2} [D]_t \\
\varphi_2 = K_{D2} - [P]_t + 2 [D]_t \\
\varphi_3 = 1\n\end{cases}
$$
\n(3)

where the subscript "t" represents the total concentration of the referred species. [P] was solved numerically from Eq. 3, rather than analytically via the cubic formula, to avoid failure due to loss of significance. With  $[P]$  in hand,  $[D]$ ,  $[PD]$ , and  $[P_2D]$  were computed from Eq. 2 and the corresponding equations of state. In the limit of no formation of the 2:1 complex (i.e.,  $K_{D2} \rightarrow \infty$ ), Eq. 3 simplifies to a quadratic, corresponding to formation of only the 1:1 complex

$$
0 = K_{D1}[P]_t + (K_{D1} - [P]_t + [D]_t)[P] + [D]^2 \tag{4}
$$

#### **Competition ESI-MS**

Analyses were performed on a Waters Q-TOF (quadrupole orthogonal acceleration–time-of-flight) micro mass spectrometer equipped with an ESI source in positive ion mode. Samples were dialyzed extensively against 0.01 M NH<sub>4</sub>HCO<sub>3</sub> (pH 8) and introduced into the ion source by direct infusion at a flow rate of 5 µl/min. The instrument operation parameters were optimized as follows: capillary voltage of 2800 V, sample cone voltage of 25 V, extraction cone voltage of 2.0 V, desolvation temperature of 90°C, source temperature of 120°C, and collision energy of 3.0 V. Nitrogen was used as nebulizing and drying gas on a pressure of 50 and 600 psi, respectively. MassLynx 4.1 software was used for data acquisition and deconvolution. A multiply charged spectra were acquired through a full scan analysis at mass range from 300 to 3000 Da and then deconvoluted by a maximum entropy procedure (*27*) to the zero-charge spectra presented. Samples were diluted with dialysate to different concentrations for acquisition and data processing under the same conditions.

#### **CD spectroscopy**

Spectra were acquired in 10 mM  $NaH_2PO_4/Na_2HPO_4$  (pH 7.4) plus NaCl as a function of concentration or temperature as indicated in the text in a Jasco J-810 instrument. Thermal denaturation experiments were performed at 45°C/hour with a response time of 32 s. The path length for near-UV scans was typically 1 or 0.1 mm for far-UV scans. Spectral analysis following blank subtraction and normalization with respect to path length and concentration was performed by singular value decomposition as follows.

For each experiment, a matrix **A** with column vectors represented by CD intensities at each protein concentration was factorized into the standard decomposition

$$
\mathbf{A} = \mathbf{U} \mathbf{\Sigma} \mathbf{V}^{\mathbf{T}} \tag{5}
$$

where the left-singular unitary matrix **U** contained the orthonormal basis spectra  $\mathbf{u}_i$  scaled by the singular values  $\sigma_i$  from the diagonal matrix **Σ**. The row vectors in the right singular unitary matrix **V<sup>T</sup>** gave the concentration- or temperature-dependent contribution of each basis spectrum to the observed data and is termed as transition vectors  $\mathbf{v}^T$  in the text. For ease and clarity of presentation, the scaling due to  $\Sigma$  is captured into the transition vector, i.e.,  $\mathbf{a} = \mathbf{u}(\sigma \mathbf{v}^T)$ (matrix multiplication is associative), which has no effect on the fitted parameters. The transition vectors were fitted to titration models describing a two-state transition with dissociation constant *K* as follows

$$
X = F_{1n}(X_n - X_1) + X_1 = F_{1n} \Delta X + X_1 \tag{6}
$$

where  $X = \sigma v^T$  and the subscripts "1" and "*n*" refer to monomer and

oligomer (*n* = 2 for dimerization), respectively. 
$$
F_{1n}
$$
 is given by  

$$
K_n = np_t^{n-1} \frac{(1 - F_{1n})^n}{F_{1n}}
$$
(7)

where  $F_{1n}$  is the fractional two-state 1-to-*n* oligomer at equilibrium and  $p_t$  is the total protein concentration. As detailed elsewhere (26), a fundamental feature of Eq. 7 is that dimerization is uniquely nonsigmoidal on linear scales, which is diagnostic for two-state dimers. Any higherorder oligomer processes are invariably sigmoidal on linear scales.

#### **Nuclear magnetic spectroscopy**

NMR experiments were conducted at 25°C using Bruker BioSpin 500, 600, or 800 MHz spectrometers. For DOSY experiments, unlabeled protein and DNA were co-dialyzed in separate compartments against the required buffer, lyophilized, and reconstituted to  $250 \mu M$ in 100% D2O before data acquisition at 500 MHz with a 5-mm total body irradiation probe. For two-dimensional (2D)/3D experiments, uniformly labeled  $\Delta$ N165 and  $\Delta$ N117 ( $\pm$  unlabeled DNA) were dialyzed against the required buffer at 11/10 excess concentration and adjusted 10%  $D_2O$  at 400 to 700  $\mu$ M protein. The dependence of the DOSY-derived self-diffusion coefficients on total protein concentration was fitted using Eq. 6, with *X* corresponding to the diffusion coefficients of the oligomer and monomer.

 ${}^{1}$ H- ${}^{15}$ N correlated measurements were made using a phasesensitive, double inept transfer with a garp decoupling sequence and solvent suppression (hsqcf3gpph19). Spectra were acquired with  $1k \times 144$  data points and zero-filled to  $4k \times 4k$ . Steady-state heteronuclear  $\rm \{ ^1H\} ^{15}N\text{-}NOE$  was acquired at 600 MHz from the difference between spectra acquired with and without  $^1\mathrm{H}$  saturation and a total recycle delay of 3 s. The data were processed with TopSpin 3.2 to extract peak intensities and fitted as single exponential decays.

Spectra were assigned with purified  ${}^{13}$ C/ ${}^{15}$ N-labeled constructs in a standard suite of 3D experiments: HNCA, HNCACB, HN(CO) CACB, HNCO, and HN(CA)CO at 800 MHz using a 5-mm TCI cryoprobe for bound protein to DNA and at 600 MHz using a 5-mm QXI resonance probe for unbound protein. Spectra were processed using NMNRFx software, referenced to 4,4-dimethyl-4-silapentane-1-sulfonate (DSS), and peak picked/analyzed with NMRFAM-Sparky. Automated Assignments were made using the NMRFAM Pine server and verified manually.

# **Fluorescence-detected self-association and protein denaturation**

The intrinsic fluorescence from three tryptophan residues in the PU.1 ETS domain was excited at 280 nm and detected at 340 nm with a slit of 15 nm for excitation and 20 nm for emission. Intensity data recorded in the vertical and horizontal polarizer positions were corrected for the grating factor and by blank subtraction. Concentrationdependent anisotropies were fitted to Eqs. 6 and 7, where  $X = \langle r \rangle$ . For denaturation studies, PU.1 at 100  $\mu$ M and 1  $\mu$ M in 10 mM tris-HCl buffer (pH 7.4) containing either 0.15 or 0.05 M NaCl was titrated with urea. Blank-subtracted intensity data were directly fitted with the linear extrapolation method.

#### **Differential scanning calorimetry**

Protein samples were exhaustively dialyzed against 10 mM NaH2PO4/ Na<sub>2</sub>HPO<sub>4</sub> (pH 7.4) and 0.05 M NaCl over 48 hours with at least three buffer changes. The final dialysate was reserved and used to rinse and fill the reference cell as well as diluent for the samples. Thermal scans were carried out at 45°C/hour from 10° to 80°C using a MicroCal VP-DSC instrument (Malvern). All scans were carried out only when the baseline was reproducibly flat. Thermograms were fitted to two-state transition models. Nonpolar and polar solvent-accessible surface area (SASA) for monomeric  $\Delta N165$  was estimated from the solution NMR structure 5W3G (*29*) based on a 1.4-Å probe. SASA for the unfolded state ensemble was provided by the ProtSA algorithm. The change in SASA in angstrom was converted to heat capacity change in kilojoule mol<sup>-1</sup> Kelvin<sup>-1</sup> using coefficients as follows

$$
\Delta C_{\rm p}^{0} = (0.32 \pm 0.04) \, \Delta A_{\rm nonpolar} - (0.14 \pm 0.04) \, \Delta A_{\rm polar} \tag{8}
$$

#### **High-precision densimetry**

Solution densities  $\rho$  were measured in 10 mM tris-HCl (pH 7.4) at 25°C, containing 150 mM NaCl using an Anton Paar model DMA-5000 vibrating tube densimeter with a precision of  $1.5 \times 10^{-6}$  g/ml. The partial molar volume of the solute *V*° was determined from the following relationship

$$
\rho = \rho_0 + (M - V^{\circ} \rho_0) c \tag{9}
$$

where  $\rho_0$  is the density of the buffer, *c* is the molar solute concentration, and *M* is the molecular weight of the solute. For a two-state dimeric species, the observed density was analyzed as follows

$$
\rho_{\rm obs} = F_{1n}\rho_2 + (1 - F_{1n})\rho_1 \tag{10}
$$

where  $F_{1n}$  is as defined by Eq. 7, with  $n = 2$ . Because the observed density varies with the concentration of any species,  $\rho_1$  and  $\rho_2$  are each treated as linear functions as described by Eq. 9.

#### **SUPPLEMENTARY MATERIALS**

Supplementary material for this article is available at [http://advances.sciencemag.org/cgi/](http://advances.sciencemag.org/cgi/content/full/6/8/eaay3178/DC1) [content/full/6/8/eaay3178/DC1](http://advances.sciencemag.org/cgi/content/full/6/8/eaay3178/DC1)

Table S1. DNA binding and self-association equilibrium constants of PU.1 constructs.

- Table S2. Primers in RT-PCR experiments.
- Fig. S1. Calibration of transgenic PU.1 dosage. Fig. S2. Characterization of a peptide-based PU.1 inhibitor.
- Fig. S3. <sup>1</sup>H-<sup>15</sup>N HSQC-detected titration of ∆N117 and ∆N165 by cognate DNA.
- Fig. S4. Purity of recombinant PU.1 constructs.
- Fig. S5. Spectral analysis of far-UV CD of  $\Delta N165$  in 0.15 and 0.05 M NaCl.
- Fig. S6. Salt-dependent line broadening of methyl protons in  $\Delta N165$ .
- Fig. S7 The short C-terminal IDR is required for DNA-free PU.1 dimerization.

Fig. S8. Effect of macromolecular crowding on dimerization of  $\Delta N165$  in the unbound and DNA-bound states.

[View/request a protocol for this paper from](https://en.bio-protocol.org/rap.aspx?eid=10.1126/sciadv.aay3178) *Bio-protocol*.

#### **REFERENCES AND NOTES**

- 1. J. Liu, N. B. Perumal, C. J. Oldfield, E. W. Su, V. N. Uversky, A. K. Dunker, Intrinsic disorder in transcription factors. *Biochemistry* **45**, 6873–6888 (2006).
- 2. G. P. Singh, D. Dash, Intrinsic disorder in yeast transcriptional regulatory network. *Proteins* **68**, 602–605 (2007).
- 3. Y. Minezaki, K. Homma, A. R. Kinjo, K. Nishikawa, Human transcription factors contain a high fraction of intrinsically disordered regions essential for transcriptional regulation. *J. Mol. Biol.* **359**, 1137–1149 (2006).
- 4. D. Vuzman, A. Azia, Y. Levy, Searching DNA via a "Monkey Bar" mechanism: The significance of disordered tails. *J. Mol. Biol.* **396**, 674–684 (2010).
- 5. M. A. E. Lohrum, D. B. Woods, R. L. Ludwig, É. Bálint, K. H. Vousden, C-terminal ubiquitination of p53 contributes to nuclear export. *Mol. Cell. Biol.* **21**, 8521–8532 (2001).
- 6. S. G. E. Roberts, I. Ha, E. Maldonado, D. Reinberg, M. R. Green, Interaction between an acidic activator and transcription factor TFIIB is required for transcriptional activation. *Nature* **363**, 741–744 (1993).
- 7. J. S. Friedman, H. Khanna, P. K. Swain, R. DeNicola, H. Cheng, K. P. Mitton, C. H. Weber, D. Hicks, A. Swaroop, The minimal transactivation domain of the basic motif-leucine zipper transcription factor NRL interacts with TATA-binding protein. *J. Biol. Chem.* **279**, 47233–47241 (2004).
- 8. S. Rogers, R. Wells, M. Rechsteiner, Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. *Science* **234**, 364–368 (1986).
- 9. P. Chevaillier, Pest sequences in nuclear proteins. *Int. J. Biochem.* **25**, 479–482 (1993).
- 10. A. Mittal, A. S. Holehouse, M. C. Cohan, R. V. Pappu, Sequence-to-conformation relationships of disordered regions tethered to folded domains of proteins. *J. Mol. Biol.* **430**, 2403–2421 (2018).
- 11. X. Guo, M. L. Bulyk, A. J. Hartemink, Intrinsic disorder within and flanking the DNA-binding domains of human transcription factors, in *Biocomputing 2012* (World Scientific, 2011), pp. 104–115.
- 12. P. B. Staber, P. Zhang, M. Ye, R. S. Welner, C. Nombela-Arrieta, C. Bach, M. Kerenyi, B. A. Bartholdy, H. Zhang, M. Alberich-Jordà, S. Lee, H. Yang, F. Ng, J. Zhang, M. Leddin, L. E. Silberstein, G. Hoefler, S. H. Orkin, B. Göttgens, F. Rosenbauer, G. Huang, D. G. Tenen, Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells. *Mol. Cell* **49**, 934–946 (2013).
- 13. H. Yuki, S. Ueno, H. Tatetsu, H. Niiro, T. Iino, S. Endo, Y. Kawano, Y. Komohara, M. Takeya, H. Hata, S. Okada, T. Watanabe, K. Akashi, H. Mitsuya, Y. Okuno, PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells. *Blood* **121**, 962–970 (2013).
- 14. H. Tatetsu, S. Ueno, H. Hata, Y. Yamada, M. Takeya, H. Mitsuya, D. G. Tenen, Y. Okuno, Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. *Cancer Res.* **67**, 5328–5336 (2007).
- 15. F. Rosenbauer, K. Wagner, J. L. Kutok, H. Iwasaki, M. M. le Beau, Y. Okuno, K. Akashi, S. Fiering, D. G. Tenen, Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. *Nat. Genet.* **36**, 624–630 (2004).
- 16. E. Gjoneska, A. R. Pfenning, H. Mathys, G. Quon, A. Kundaje, L. H. Tsai, M. Kellis, Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. *Nature* **518**, 365–369 (2015).
- 17. T. Wohlfahrt, S. Rauber, S. Uebe, M. Luber, A. Soare, A. Ekici, S. Weber, A. E. Matei, C. W. Chen, C. Maier, E. Karouzakis, H. P. Kiener, E. Pachera, C. Dees, C. Beyer, C. Daniel, K. Gelse, A. E. Kremer, E. Naschberger, M. Stürzl, F. Butter, M. Sticherling, S. Finotto, A. Kreuter, M. H. Kaplan, A. Jüngel, S. Gay, S. L. Nutt, D. W. Boykin, G. M. K. Poon, O. Distler, G. Schett, J. H. W. Distler, A. Ramming, PU.1 controls fibroblast polarization and tissue fibrosis. *Nature* **566**, 344–349 (2019).
- 18. I. Antony-Debre, A. Paul, J. Leite, K. Mitchell, H. M. Kim, L. A. Carvajal, T. I. Todorova, K. Huang, A. Kumar, A. A. Farahat, B. Bartholdy, S. R. Narayanagari, J. Chen, A. Ambesi-Impiombato, A. A. Ferrando, I. Mantzaris, E. Gavathiotis, A. Verma, B. Will, D. W. Boykin, W. D. Wilson, G. M. Poon, U. Steidl, Pharmacological inhibition ofthe transcription factor PU.1 inleukemia.1 in leukemia. *J. Clin. Invest.* **127**, 4297–4313 (2017).
- 19. S. Durual, A. Rideau, S. Ruault-Jungblut, D. Cossali, P. Beris, V. Piguet, T. Matthes, Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts. *Leukemia* **21**, 1050–1059 (2007).
- 20. S. Esaki, M. G. Evich, N. Erlitzki, M. W. Germann, G. M. K. Poon, Multiple DNA-binding modes for the ETS family transcription factor PU.1. *J. Biol. Chem.* **292**, 16044–16054  $(2017)$
- 21. G. M. K. Poon, DNA binding regulates the self-association of the ETS domain of PU.1 in a sequence-dependent manner. *Biochemistry* **51**, 4096–4107 (2012).
- 22. H. Y. Kueh, A. Champhekar, S. L. Nutt, M. B. Elowitz, E. V. Rothenberg, Positive feedback between PU.1 and the cell cycle controls myeloid differentiation. *Science* **341**, 670–673 (2013).
- 23. H. Chen, D. Ray-Gallet, P. Zhang, C. J. Hetherington, D. A. Gonzalez, D. E. Zhang, F. Moreau-Gachelin, D. G. Tenen, PU.1 (Spi-1) autoregulates its expression in myeloid cells. *Oncogene* **11**, 1549–1560 (1995).
- 24. L. A. Solomon, S. Podder, J. He, N. L. Jackson-Chornenki, K. Gibson, R. G. Ziliotto, J. Rhee, R. P. De Koter, Coordination of myeloid differentiation with reduced cell cycle progression by PU.1 induction of MicroRNAs targeting cell cycle regulators and lipid anabolism. *Mol. Cell. Biol.* **37**, e00013-17 (2017).
- 25. X. Jia, L. K. Lee, J. Light, A. G. Palmer III, N. Assa-Munt, Backbone dynamics of a short PU.1 ETS domain. *J. Mol. Biol.* **292**, 1083–1093 (1999).
- 26. G. M. K. Poon, Enhancement of oligomeric stability by covalent linkage and its application to the human p53tet domain: Thermodynamics and biological implications. *Biochem. Soc. Trans.* **35**, 1574–1578 (2007).
- 27. A. G. Ferrige, M. J. Seddon, B. N. Green, S. A. Jarvis, J. Skilling, J. Staunton, Disentangling electrospray spectra with maximum-entropy. *Rapid Commun. Mass Spectrom.* **6**, 707–711 (1992).
- 28. M. V. Berjanskii, D. S. Wishart, Application of the random coil index to studying protein flexibility. *J. Biomol. NMR* **40**, 31–48 (2008).
- 29. C. Perez-Borrajero, C. S.-H. Lin, M. Okon, K. Scheu, B. J. Graves, M. E. P. Murphy, L. P. McIntosh, The biophysical basis for phosphorylation-enhanced DNA-binding autoinhibition of the ETS1 transcription factor. *J. Mol. Biol.* **431**, 593–614 (2019).
- 30. W. Huang, E. Horvath, E. A. Eklund, PU.1, interferon regulatory factor (IRF) 2, and the nterferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells. *J. Biol. Chem.* **282**, 6629–6643 (2007).
- 31. J. M. Pongubala, C. van Beveren, S. Nagulapalli, M. J. Klemsz, S. McKercher, R. A. Maki, M. L. Atchison, Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. *Science* **259**, 1622–1625 (1993).
- 32. L. Warren, D. Bryder, I. L. Weissman, S. R. Quake, Transcription factor profiling in individual hematopoietic progenitors by digital RT-PCR. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 17807–17812 (2006).
- 33. C. S. Furfine, S. F. Velick, The acyl-enzyme intermediate andthe kinetic mechanism ofthe glyceraldehyde 3-phosphate dehydrogenase reaction. *J. Biol. Chem.* **240**, 844–855 (1965).
- 34. B. U. Mueller, T. Pabst, J. Fos, V. Petkovic, M. F. Fey, N. Asou, U. Buergi, D. G. Tenen, ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. *Blood* **107**, 3330–3338 (2006).
- 35. T. V. Pedchenko, G. Y. Park, M. Joo, T. S. Blackwell, J. W. Christman, Inducible binding of PU.1 and interacting proteins to the Toll-like receptor 4 promoter during endotoxemia. *Am. J. Phys. Lung Cell. Mol. Phys.* **289**, L429–L437 (2005).
- 36. B. Will, T. O. Vogler, S. Narayanagari, B. Bartholdy, T. I. Todorova, M. da Silva Ferreira, J. Chen, Y. Yu, J. Mayer, L. Barreyro, L. Carvajal, D. B. Neriah, M. Roth, J. van Oers, S. Schaetzlein, C. McMahon, W. Edelmann, A. Verma, U. Steidl, Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. *Nat. Med.* **21**, 1172–1181 (2015).
- 37. T. A. Lodie, R. Savedra Jr., D. T. Golenbock, C. P. Van Beveren, R. A. Maki, M. J. Fenton, Stimulation of macrophages by lipopolysaccharide alters the phosphorylation state, conformation, and function of PU.1 via activation of casein kinase II. *J. Immunol.* **158**, 1848–1856 (1997).
- 38. M. Hamdorf, A. Berger, S. Schule, J. Reinhardt, E. Flory, PKC  $\delta$  induced PU.1 phosphorylation promotes hematopoietic stem cell differentiation to dendritic cells. *Stem Cells* **29**, 297–306 (2011).
- 39. A. Seshire, T. Rößiger, M. Frech, S. Beez, H. Hagemeyer, E. Puccetti, Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding. *Leukemia* **26**, 1338–1347 (2012).
- 40. Y. Arinobu, S.-i. Mizuno, Y. Chong, H. Shigematsu, T. Iino, H. Iwasaki, T. Graf, R. Mayfield, S. Chan, P. Kastner, K. Akashi, Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. *Cell Stem Cell* **1**, 416–427 (2007).
- 41. C. W. Liew, K. D. Rand, R. J. Y. Simpson, W. W. Yung, R. E. Mansfield, M. Crossley, M. Proetorius-Ibba, C. Nerlov, F. M. Poulsen, J. P. Mackay, Molecular analysis of the interaction between the hematopoietic master transcription factors GATA-1 and PU.1. *J. Biol. Chem.* **281**, 28296–28306 (2006).
- 42. M. Fuxreiter, Fuzziness in protein interactions—A historical perspective. *J. Mol. Biol.* **430**, 2278–2287 (2018).
- 43. B. A. Shoemaker, J. J. Portman, P. G. Wolynes, Speeding molecular recognition by using the folding funnel: The fly-casting mechanism. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 8868–8873 (2000).
- 44. J. M. Perkel, M. L. Atchison, A two-step mechanism for recruitment of Pip by PU.1. *J. Immunol.* **160**, 241–252 (1998).
- 45. S. L. Currie, D. K. W. Lau, J. J. Doane, F. G. Whitby, M. Okon, L. P. McIntosh, B. J. Graves, Structured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5. *Nucleic Acids Res.* **45**, 2223–2241 (2017).
- 46. E. P. Lamber, L. Vanhille, L. C. Textor, G. S. Kachalova, M. H. Sieweke, M. Wilmanns, Regulation of the transcription factor Ets-1 by DNA-mediated homo-dimerization. *EMBO J.* **27**, 2006–2017 (2008).
- 47. M. A. Pufall, G. M. Lee, M. L. Nelson, H.-S. Kang, A. Velyvis, L. E. Kay, L. P. Mc Intosh, B. J. Graves, Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region. *Science* **309**, 142–145 (2005).
- 48. D. A. King, L. Zhang, L. Guarente, R. Marmorstein, Structure of a HAP1-DNA complex reveals dramatically asymmetric DNA binding by a homodimeric protein. *Nat. Struct. Biol.* **6**, 64–71 (1999).
- 49. J. C. Kwok, J. Perdomo, B. H. Chong, Identification of a monopartite sequence in PU.1 essential for nuclear import, DNA-binding and transcription of myeloid-specific genes. *J. Cell. Biochem.* **101**, 1456–1474 (2007).

**Acknowledgments:** We thank D. Beckett and W. D. Wilson for insightful discussions and L. McIntosh for providing a structure of the unbound PU.1 ETS monomer (5W3G) before publication. We also acknowledge with appreciation the many excellent suggestions from the reviewers. NMR data presented here were collected, in part, at the City University of New York Advanced Science Research Center (CUNY ASRC) Biomolecular NMR Facility. **Funding:** This investigation was supported by NSF grant MCB 15451600 and NIH grant R21 HL129063 to G.M.K.P. S.X., H.M.K., and S.E. were partially supported by GSU Molecular Basis of Diseases Fellowships. V.T.L.H. was supported by the GSU University Assistantship Program. **Author contributions:** S.L. and H.M.K. carried out cell-based studies. G.M.K.P. cloned the molecular constructs. S.X. and S.E. expressed and purified the recombinant protein constructs. S.X., S.E., J.M.A., and M.W.G. performed and analyzed the NMR experiments. S.W. performed and analyzed the data from the ESI-MS studies. V.L.T.H. performed the densimetric experiments and analyzed the volumetric data. S.X., M.K., G.L.F., and A.V.A. performed the binding, thermodynamic, and other spectroscopic experiments. S.X., M.W.G., and G.M.K.P. jointly designed the studies, analyzed data, composed the figures, and wrote the paper. **Competing interests:** The authors declare that they have no competing interests. **Data and materials** 

**availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Submitted 10 June 2019 Accepted 4 December 2019 Published 21 February 2020 10.1126/sciadv.aay3178

**Citation:** S. Xhani, S. Lee, H. M. Kim, S. Wang, S. Esaki, V. L. T. Ha, M. Khanezarrin, G. L. Fernandez, A. V. Albrecht, J. M. Aramini, M. W. Germann, G. M. K. Poon, Intrinsic disorder controls two functionally distinct dimers of the master transcription factor PU.1. *Sci. Adv.* **6**, eaay3178 (2020).